Chinese CDMO contracted to manufacture Pfizer’s oncology candidate

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/bluebay2014)
(Image: Getty/bluebay2014)

Related tags: CDMO, Pfizer, Cancer, CMAB Biopharma, Kintor Pharmaceuticals

CMAB Biopharma to support Kintor in the clinical development of a potential treatment for liver cancer, ahead of regulatory filing.

Kintor Pharmaceuticals, a Suzhou, China-based R&D company, has reached a collaboration agreement with the Chinese contract development and manufacturing organisation (CDMO) CMAB Biopharma, for the development of activin receptor-like kinase-1 (ALK-1) antibody.

This antibody is a humanized monoclonal antibody (mAb) targeting tumor angiogenesis, initially developed by Pfizer. Kintor was licensed exclusive worldwide rights by Pfizer to develop, manufacture, and commercialize ALK-1 in January 2018, and launched​ Phase II clinical trials for the product in May 2019 in Taiwan.

The drug is currently being tested in combination with nivolumab, in patients with hepatocellular carcinoma (HCC).

Under the agreement, CMAB will provide research and manufacturing services to support clinical development using its cell line development platform. It also will support commercialization and marketing of the product, upon regulatory approvals.

According to CMAB, the companies will work collaboratively in an aim to meet the investigational new drug (IND) application requirements of Chinese and US regulators.

ALK-1 is expressed primarily on vascular endothelial cells and is related to the growth and migration of endothelial cells. By blocking the receptor, ALK-1 can inhibit cancer blood vessel growth, blood flow, and tumor angiogenesis, thus effectively slowing down tumor growth.

During two Phase I clinical trials conducted from 2007 until 2014 by Pfizer in the US, Italy, South Korea, and Japan, the drug demonstrated ‘reasonable’ clinical benefits, according to CMAB, with the potential to be the first fully human therapeutic monoclonal antibody in the world targeting ALK-1.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Related suppliers

Follow us

Products

View more

Webinars